People: Perrigo Co (PRGO.O)
PRGO.O on Nasdaq
119.48USD
17 May 2013
119.48USD
17 May 2013
Price Change (% chg)
$-0.33 (-0.28%)
$-0.33 (-0.28%)
Prev Close
$119.81
$119.81
Open
$120.32
$120.32
Day's High
$120.74
$120.74
Day's Low
$119.22
$119.22
Volume
493,749
493,749
Avg. Vol
515,400
515,400
52-wk High
$121.33
$121.33
52-wk Low
$98.25
$98.25
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Joseph Papa |
57 | 2007 | Chairman of the Board, President, Chief Executive Officer |
Judy Brown |
44 | 2006 | Chief Financial Officer, Executive Vice President |
Todd Kingma |
52 | 2006 | Executive Vice President, General Counsel, Secretary |
Douglas Boothe |
2013 | Executive Vice President, General Manager - Perrigo Pharmaceuticals | |
Scott Jamison |
56 | 2011 | Executive Vice President, General Manager - Nutritionals |
Sharon Kochan |
44 | 2012 | Executive Vice President, General Manager - International |
Jeffrey Needham |
56 | 2009 | Executive Vice President, General Manager - Consumer Healthcare |
John Hendrickson |
49 | 2007 | Executive Vice President - Global Operations and Supply Chain |
Thomas Farrington |
55 | 2006 | Senior Vice President, Chief Information Officer |
Jatin Shah |
59 | 2005 | Senior Vice President, Chief Scientific Officer |
Michael Stewart |
60 | 2004 | Senior Vice President - Global Human Resources |
Louis Yu |
62 | 2006 | Senior Vice President - Global Quality and Compliance |
Gary Kunkle |
65 | 2009 | Lead Independent Director |
Jacqualyn Fouse |
51 | 2012 | Director |
Laurie Brlas |
55 | 2003 | Independent Director |
Gary Cohen |
53 | 2009 | Independent Director |
David Gibbons |
69 | 2007 | Independent Director |
Ran Gottfried |
68 | 2006 | Independent Director |
Ellen Hoffing |
55 | 2008 | Independent Director |
Michael Jandernoa |
2007 | Independent Director | |
Herman Morris |
61 | 1999 | Independent Director |
Ben-Zion Zilberfarb |
62 | 2007 | Independent Director |
Arthur Shannon |
IR Contact Officer |
Biographies
| Name | Description |
|---|---|
Joseph Papa |
Mr. Joseph C. Papa is Chairman of the Board, President, Chief Executive Officer of Perrigo Company. Mr. Papa joined Perrigo in October 2006 as President and Chief Executive Officer, was elected to the Board of Directors in November 2006 and was appointed Chairman of the Board in October 2007. He previously served as Chairman and Chief Executive Officer of the Pharmaceutical and Technologies Services segment of Cardinal Health, Inc. from December 2004 to October 2006. Prior to that position he served as President and Chief Operating Officer of Watson Pharmaceuticals, Inc. from 2001 to 2004. Additionally, he has held management positions at DuPont Pharmaceuticals, Pharmacia Corporation, G.D. Searle & Company and Novartis AG. Mr. Papa has been a director of Smith & Nephew, a developer of advanced orthopedic medical devices since August 2008. |
Judy Brown |
Ms. Judy L. Brown is Chief Financial Officer, Executive Vice President of Perrigo Company. She served as Vice President and Corporate Controller from September 2004 to July 2006. Previously, Ms. Brown held various senior positions in finance and operations at Whirlpool Corporation from 1998 to August 2004. Ms. Brown is a director of Belden Corporation, an NYSE traded company, that designs, manufactures and markets cable, connectivity and networking products in markets including industrial automation, enterprise, transportation, infrastructure and consumer electronics. |
Todd Kingma |
Mr. Todd W. Kingma is Executive Vice President, General Counsel and Secretary of Perrigo Company. Mr. Kingma was named Executive Vice President in May 2006. He served as Vice President, General Counsel and Secretary from August 2003 to May 2006. Previously, Mr. Kingma held various positions at Pharmacia Corporation from 1991 through August 2003. His last position with Pharmacia Corporation was Vice President and Associate General Counsel, Global Specialty Operations. |
Douglas Boothe |
Mr. Douglas Boothe has been appointed as Executive Vice President, General Manager - Perrigo Pharmaceuticals of Perrigo Co. effective December 4, 2012. Prior to joining Perrigo, Doug served as Chief Executive Officer of Actavis Inc., where he was responsible for all aspects of the company's generics business in North America and Latin America, including sales, marketing, supply chain, quality, finance, legal, IT, regulatory affairs, human resources and intellectual property. He also has served in strategic planning and business development leadership roles for Alpharma Inc., Pharmacia Corporation and Xerox Corporation. Doug has a Bachelor of Science Degree in Mechanical and Aerospace Engineering from Princeton University and a Master of Business Administration in Marketing Management and Strategic Planning from the University of Pennsylvania's Wharton School of Business. |
Scott Jamison |
Mr. Scott F. Jamison is Executive Vice President, General Manager - Nutritionals of Perrigo Company, since January 2011. Before the Company acquired PBM in fiscal 2010, Mr. Jamison had served as PBM's Executive Vice President and General Counsel since the formation of PBM in 1997 and was a key member of the executive team throughout the evolution and growth of PBM. In addition to his legal responsibilities, Mr. Jamison has held senior leadership responsibilities in operations and sales, as well as in new business and product development. |
Sharon Kochan |
Mr. Sharon Kochan is Executive Vice President and General Manager, International of Perrigo Company. He served as Executive Vice President, General Manager of Rx Pharmaceuticals from March 2007 to July 2012 and as Senior Vice President of Business Development and Strategy from March 2005 to March 2007. Mr. Kochan was Vice President, Business Development of Agis Industries (1983) Ltd. from July 2001 until the acquisition of Agis by the Company in March 2005. |
Jeffrey Needham |
Mr. Jeffrey R. Needham is Executive Vice President, General Manager - Consumer Healthcare of Perrigo Company. He served as Senior Vice President of Commercial Business Development from March 2005 through October 2009. Previously, he served as Senior Vice President of International from November 2004 to March 2005. He served as Managing Director of Perrigo’s U.K. operations from May 2002 to November 2004 and as Vice President of Marketing from 1993 to 2002. |
John Hendrickson |
Mr. John T. Hendrickson is Executive Vice President - Global Operations and Supply Chain of Perrigo Company. He served as Executive Vice President and General Manager, Perrigo Consumer Healthcare from August 2003 to March 2007. He served as Executive Vice President of Operations from October 1999 to August 2003. |
Thomas Farrington |
Mr. Thomas M. Farrington is Senior Vice President and Chief Information Officer of Perrigo Company. He formerly served as Chief Information Officer for F. Dohmen Co. in addition to serving as a division President for JASCORP LLC from March 2003 to October 2006. Prior to that position, Mr. Farrington held various senior positions in information technology and finance at Dell, Inc. from 1999 to 2003. |
Jatin Shah |
Dr. Jatin Shah, Ph.D., is Senior Vice President and Chief Scientific Officer of Perrigo Company. He served as Vice President of Research and Development for Rx products from February 2004 to June 2005. Previously, Dr. Shah held various senior positions in Research and Development at Mayne Pharma (known previously as Faulding Pharmaceuticals) from June 1996 to January 2004. |
Michael Stewart |
Mr. Michael R. Stewart is Senior Vice President - Global Human Resources of Perrigo Company. He served as Vice President, Human Resources from July 1993 to September 2004. Mr. Stewart began his employment with the Company in August 1981. |
Louis Yu |
Dr. Louis W. Yu, Ph.D., is Senior Vice President - Global Quality and Compliance of Perrigo Company. Previously, Dr. Yu served from October 2005 to October 2006 as Vice President, Quality at CV Therapeutics Inc. Prior to that position, he served as Global Head of Quality & Compliance for Forest Laboratories, Inc. from April 1999 to October 2005. He served as the Vice President, Quality & Compliance for Solvay Pharmaceuticals between October 1996 and March 1999. Currently, he is associated with the University of Wisconsin, serving as Adjunct Professor, Extension Services in Pharmacy, School of Pharmacy. |
Gary Kunkle |
Mr. Gary K. Kunkle Jr., serves as the Lead Independent Director of Perrigo Company. He has been a director of Perrigo since October 2002 and has served as Lead Independent Director from August 2007 to August 2008 and since August 2009. He also served as the Chair of the Compensation Committee from May 2006 until October 2007. Mr. Kunkle served as Chairman and Chief Executive Officer of DENTSPLY International Inc., a manufacturer and marketer of products for the professional dental market, from January 2004 until his retirement in December 2006. He previously served as President and Chief Operating Officer of DENTSPLY from January 1997 to December 2003. He also was a director of that company from March 2002 until December 2006. From January 1994 to December 1996, he served as President of Vistakon, a division of Johnson & Johnson. |
Jacqualyn Fouse |
Ms. Jacqualyn A. Fouse, Ph.D. has been appointed as the Director of Perrigo Co. She has served as Executive Vice President and Chief Financial Officer of Celgene Corporation, a global biopharmaceutical company, since September of 2010. From July 2007 until September 2010, she previously served as Chief Financial Officer for Bunge Ltd., a global agribusiness and food company. From 2002 to July 2007, Ms. Fouse served as Senior Vice President, Chief Financial Officer and Corporate Strategy, at Alcon Laboratories, a eye care company. Prior to Alcon Laboratories, Ms. Fouse was Chief Financial Officer of Swissair Group in Switzerland, 2001 -- 2002, and she was Group Treasurer of Nestle S.A. in Switzerland from 1999 to 2001. Ms. Fouse held various senior level financial positions in both the U.S. and Switzerland with both Alcon and Nestle form 1986 to 1999. She also held positions with LTV Aerospace and Defense and Celanese Chemical Company from 1983 to 1986. Ms. Fouse currently serves on the Board of Dick's Sporting Goods, a U.S. retailer of sporting goods and athletic apparel. |
Laurie Brlas |
Ms. Laurie Brlas is Independent Director of Perrigo Company. She has served as Chair of the Audit Committee since October 2004. Since March 2008, Ms. Brlas has served as Executive Vice President, Chief Financial Officer, effective October 1, 2012, Ms. Brlas will serve as Executive Vice President and President of Global Operations of Cliffs Natural Resources, Inc. (formerly Cleveland-Cliffs, Inc.), the producer of iron ore pellets in North America. Previously at Cliffs Natural Resources, Inc., Ms. Brlas served as Senior Vice President, Chief Financial Officer from December 2006 to March 2008 and Senior Vice President, Chief Financial Officer and Treasurer from December 2006 to November 2007. Prior to that Ms. Brlas served as Senior Vice President and Chief Financial Officer of STERIS Corporation from April 2000 through November 2006. From September 1995 through March 2000, Ms. Brlas held various positions with Office Max, Inc., most recently as Senior Vice President and Corporate Controller. Ms. Brlas also served as a director for Nova Chemicals from September 2008 to July 2009. |
Gary Cohen |
Mr. Gary M. Cohen is Independent Director of Perrigo Company. He has been a director of Perrigo since January 2003 and served as Lead Independent Director from August 2008 to August 2009. Since June 2006, he has served as Executive Vice President of Becton, Dickinson and Company (“BD”), a provider of medical supplies, devices, laboratory equipment and diagnostic systems. He also served as President of BD Medical, one of three business segments of BD, from May 1999 until June 2006. Mr. Cohen has been an executive officer of BD in various capacities since October 1996. Mr. Cohen presently serves as chairperson of the Centers for Disease Control and Prevention (CDC) Foundation, director and secretary of the United States Fund for UNICEF, a director of the Accordia Global Health Foundation, director of GBCHealth, and also serves as a Commissioner on the UN Commission on Life-Saving Commodities, chairperson of the CDC Corporate Roundtable and an Advisor to the Clinton Global Initiative and the Massachusetts General Hospital Center for Global Health. |
David Gibbons |
Mr. David T. Gibbons is Independent Director of Perrigo Company. Between March 2008 and February 2009, he served as Interim Chief Executive Officer of Cott Corporation, a provider of non-alcoholic beverages and store brand soft drinks. He has served on Cott’s Board of Directors since 2007 and is currently Chairman of the Board. Mr. Gibbons served as Executive Chairman of Perrigo from October 9, 2006 until his retirement in March 2007. Prior to that, Mr. Gibbons served as the President and Chief Executive Officer of Perrigo from May 2000 to October 2006 and as Chairman of the Board from August 2003 to October 2007. He served as President of Rubbermaid Europe from August 1997 to April 1999 and as President of Rubbermaid Home Products from December 1995 to August 1997. Prior to joining Rubbermaid, Mr. Gibbons served in a variety of general management, sales and marketing positions during his 27-year career with 3M Company. Mr. Gibbons was also a director of Robbins & Myers, Inc., a supplier of application-critical equipment and systems to the global pharmaceutical, energy and industrial markets, from March 2004 to January 2010, and had served as a director of Banta Corp, a diversified printing company, from 2003 to 2006. |
Ran Gottfried |
Mr. Ran Gottfried is Independent Director of Perrigo Company since February 21, 2006. From July 2006 until December 2008, Mr. Gottfried served as Chairman and CEO of Powerpaper Ltd., a developer and manufacturer of micro electrical cosmetic and pharmaceutical patches. Since 1975 he has served as a CEO, consultant and director of private companies in Israel and Europe in the areas of retail and distribution, pharmaceuticals, and telecommunications. From January 2001 until December 2005, he served as Chairman of Magnolia Silver Jewelry, Ltd. Mr. Gottfried also served as an advisor to Careline-Neca, a consumer division of Perrigo’s Israeli subsidiary from 2004 until March 2007, when his consulting ended. Mr. Gottfried was a director of Agis from 2003 until its acquisition by Perrigo in March 2005. Mr. Gottfried was also a director of Bezeq, an Israeli telecommunications provider from November 2005 until April 2010. Mr. Gottfried resides in Israel. |
Ellen Hoffing |
Ms. Ellen Randi Hoffing is Independent Director of Perrigo Company. Since September 2009, Ms. Hoffing has served as Chief Operating Officer and Co-President of Neos Therapeutics, a privately held specialty pharmaceutical company that focuses on extended release liquid and orally disintegrating tablet drug development. From September 2006 until September 2009, she served as President and Chief Executive Officer of Applied NeuroSolutions, Inc., a development stage biopharmaceutical company focused on diagnostics and therapeutics for the treatment of Alzheimer’s disease. She has also served as Chairman of Applied NeuroSolutions’ Board of Directors from December 2007 to January 2011. Ms. Hoffing’s experience in the pharmaceutical industry includes senior positions at American Pharmaceutical Partners, from March 2005 to November 2005, Baxter Healthcare, from November 2002 to March 2005, and G.D. Searle, from September 1983 to October 2000. |
Michael Jandernoa |
Mr. Michael J. Jandernoa is Independent Director of Perrigo Company since January 1981. He has served as the Chair of the Compensation Committee since October 2007. He served as Perrigo’s Chief Executive Officer from February 1988 through April 2000 and as Chairman of the Board from October 1991 to August 2003. Mr. Jandernoa also served in various other executive capacities with Perrigo since 1979. He is a general partner of Bridge Street Capital Fund 1, LLP; was a director of Fifth Third Bank – West Michigan, a Michigan banking corporation, from December 2004 to December 2009; and a director of Steelcase, Inc., a manufacturer of casegood products and furniture systems for the office furniture industry from June 2002 to March 2010. Mr. Jandernoa served on the Board of the Strategic Economic Investment and Commercial Board (SEIC) (formerly Michigan Technology Tri-Corridor) through early 2011. He currently serves as First Vice Chair of the Business Leaders of Michigan, Inc. Mr. Jandernoa also serves on several private company boards. Leadership, operating and marketing experience – former Chief Executive Officer and Chairman of the Board of Perrigo Company as well as current leadership roles in numerous other businesses related to the pharmaceutical industry. Board and corporate governance experience – board and corporate governance experience from current and previous service as a Chairman of the Board and a director of public, private and non-profit companies and organizations with experience on Audit, Nominating & Governance and Compensation Committees. Industry knowledge – former CEO and Chairman of Perrigo Company with experience and knowledge in the development and marketing of store brand consumer healthcare products. |
Herman Morris |
Mr. Herman Morris Jr. is Independent Director of Perrigo Company. He has been a director of Perrigo since December 1999 and has served as Chair of the Nominating & Governance Committee since October 2007. Since October 2009 he has been City Attorney of the City of Memphis. From September 2006 to October 2009, he was in the private practice of law in Memphis, Tennessee. From April 2006 to September 2006, Mr. Morris was Vice President and General Counsel of Pinnacle Airlines. Mr. Morris was a partner in the Baker, Donaldson, Bearman, Caldwell and Berkowitz law firm in Memphis, Tennessee from April 2004 to June 2006. He served as President and Chief Executive Officer of Memphis Light, Gas and Water Division from August 1997 until January 2004. Prior to that, Mr. Morris was General Counsel of Memphis Light, Gas and Water Division. |
Ben-Zion Zilberfarb |
Prof. Ben-Zion Zilberfarb Ph.D., is Independent Director of Perrigo Company. Since 1978 he has served as a consultant and director for private and public companies in the areas of banking, insurance and private capital. He also has served as a Professor of Economics at Bar-Ilan University and the Edmond de Rothschild Professor of Global Asset Management at Netanya Academic College since 1988 and 2004, respectively. From 1998 to 1999 he was Director General of Israel’s Ministry of Finance. He is a Board member and Chairman of the Audit Committee and member of the Finance Committee for Delek Group, a holding and management company investing in Israel and abroad; a Board member and Chairman of the Finance Committee for Brimag Digital Age, a distributor of electrical appliances, from 2004 to 2007 and since February 2012; and a Board member and Chairman of the Finance Committee for Engel Resources, a construction company, since January 2011; each trade on the Tel-Aviv Stock Exchange. He was a Board member and Chairman of the Risk Management Committee for the Israel Discount Bank from 2006 to 2012, a Board member and Audit Committee member of FundTech, Ltd. from 2002 to 2007, and a Board member and Chairman of the Audit Committee of Partner Communication, a cellular phone company, from 2000 to 2006. |
Arthur Shannon |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Joseph Papa |
6,232,850 |
Judy Brown |
2,087,880 |
Todd Kingma |
1,657,690 |
Douglas Boothe |
-- |
Scott Jamison |
-- |
Sharon Kochan |
-- |
Jeffrey Needham |
1,217,320 |
John Hendrickson |
1,426,200 |
Thomas Farrington |
-- |
Jatin Shah |
-- |
Michael Stewart |
-- |
Louis Yu |
-- |
Gary Kunkle |
-- |
Jacqualyn Fouse |
-- |
Laurie Brlas |
-- |
Gary Cohen |
-- |
David Gibbons |
3,011,820 |
Ran Gottfried |
-- |
Ellen Hoffing |
-- |
Michael Jandernoa |
434,606 |
Herman Morris |
-- |
Ben-Zion Zilberfarb |
-- |
Arthur Shannon |
-- |
As Of 29 Jun 2012
Options Compensation
| Name | Options | Value |
|---|---|---|
Joseph Papa |
65,000 | 5,251,160 |
Judy Brown |
10,520 | 851,375 |
Todd Kingma |
24,043 | 1,731,040 |
Douglas Boothe |
0 | 0 |
Scott Jamison |
0 | 0 |
Sharon Kochan |
0 | 0 |
Jeffrey Needham |
11,065 | 676,671 |
John Hendrickson |
258,024 | 1,656,262 |
Thomas Farrington |
0 | 0 |
Jatin Shah |
0 | 0 |
Michael Stewart |
0 | 0 |
Louis Yu |
0 | 0 |
Gary Kunkle |
0 | 0 |
Jacqualyn Fouse |
0 | 0 |
Laurie Brlas |
0 | 0 |
Gary Cohen |
0 | 0 |
David Gibbons |
1,516,035 | 12,404,177 |
Ran Gottfried |
0 | 0 |
Ellen Hoffing |
0 | 0 |
Michael Jandernoa |
357,498 | 0 |
Herman Morris |
0 | 0 |
Ben-Zion Zilberfarb |
0 | 0 |
Arthur Shannon |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
STEWART MICHAEL ROBERT |
100 | $119.70 |
STEWART MICHAEL ROBERT |
200 | $119.66 |
STEWART MICHAEL ROBERT |
200 | $119.62 |
GOTTFRIED RAN |
340 | $119.57 |
STEWART MICHAEL ROBERT |
100 | $119.58 |
GOTTFRIED RAN |
258 | $119.54 |
GOTTFRIED RAN |
502 | $119.49 |
GOTTFRIED RAN |
186 | $119.61 |
GOTTFRIED RAN |
228 | $119.58 |
STEWART MICHAEL ROBERT |
200 | $119.69 |
STEWART MICHAEL ROBERT |
32 | $119.72 |
STEWART MICHAEL ROBERT |
200 | $119.59 |
STEWART MICHAEL ROBERT |
400 | $119.67 |
STEWART MICHAEL ROBERT |
60 | $119.60 |
STEWART MICHAEL ROBERT |
97 | $119.77 |
STEWART MICHAEL ROBERT |
300 | $119.69 |
GOTTFRIED RAN |
100 | $119.53 |
STEWART MICHAEL ROBERT |
1,300 | $119.68 |
GOTTFRIED RAN |
400 | $119.50 |
STEWART MICHAEL ROBERT |
100 | $119.65 |
STEWART MICHAEL ROBERT |
100 | $119.67 |
STEWART MICHAEL ROBERT |
100 | $119.62 |
GOTTFRIED RAN |
210 | $119.52 |
STEWART MICHAEL ROBERT |
403 | $119.76 |
STEWART MICHAEL ROBERT |
100 | $119.70 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
